FIELD: organic chemistry.
SUBSTANCE: invention relates to the field of organic chemistry, namely to a compound of formula 1 or its pharmaceutically acceptable salt, where R1 is a C2-C5 alkyl. The invention also relates to a pharmaceutical composition based on a compound of formula 1, its use for the preparation of a drug and to a method for the treatment or prevention of these diseases.
EFFECT: excellent agonistic activity against melanocortin receptors, manifested by the formula 1 compound, which can be used to prevent or treat obesity, diabetes, inflammation and erectile dysfunction.
Formula 1
19 cl, 10 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
BENZYLPHENYLCYCLOHEXANE DERIVATIVES AND METHODS OF THEREOF APPLICATION | 2008 |
|
RU2505521C2 |
PIPERAZINE DERIVATIVE | 2016 |
|
RU2731913C2 |
SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
PRODRUG OF FLUORINE-CONTAINING AMINO ACID | 2013 |
|
RU2639868C1 |
NOVEL AMIDE DERIVATIVE FOR INHIBITING GROWTH OF CANCER CELLS | 2008 |
|
RU2434010C2 |
LIGAND CONJUGATE WITH CYTOTOXIC DRUG PREPARATION, METHOD AND APPLICATION THEREOF | 2016 |
|
RU2708461C2 |
NEW BIPHENYL COMPOUND OR ITS SALT | 2018 |
|
RU2765152C2 |
AMINOPYRIMIDINE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2826628C1 |
FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2014 |
|
RU2704112C2 |
Authors
Dates
2022-12-26—Published
2020-11-06—Filed